Apixaban with antiplatelet therapy after acute coronary syndrome.

Alexander, John H;Lopes, Renato D;James, Stefan;Kilaru, Rakhi;Dangoisse, Vincent;et.al.
(2011) New England Journal of Medicine — Vol. 365, n° 8, p. 699-708 (2011)

Files

AlexanderJH-NEJM2011.pdf
  • Restricted Access
  • Adobe PDF
  • 622.15 KB
Request a copy

Details

Authors
  • Alexander, John H
    Author
  • Lopes, Renato D
    Author
  • James, Stefan
    Author
  • Kilaru, Rakhi
    Author
  • Dangoisse, VincentUCLouvain
    Collaborator
Show more
Abstract
The addition of apixaban, at a dose of 5 mg twice daily, to antiplatelet therapy in high-risk patients after an acute coronary syndrome increased the number of major bleeding events without a significant reduction in recurrent ischemic events. (Funded by Bristol-Myers Squibb and Pfizer; APPRAISE-2 ClinicalTrials.gov number, NCT00831441.).
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Alexander, J. H., Lopes, R. D., James, S., Kilaru, R., He, Y., Mohan, P., Bhatt, D. L., Goodman, S., Verheugt, F. W., Flather, M., Huber, K., Liaw, D., Husted, S. E., Lopez-Sendon, J., De Caterina, R., Jansky, P., Darius, H., Vinereanu, D., Cornel, J. H., et al. (2011). Apixaban with antiplatelet therapy after acute coronary syndrome. New England Journal of Medicine, 365(8), 699-708. https://doi.org/10.1056/NEJMoa1105819 (Original work published 2011)